# US 2010/0074934 A1 · Medical implants with a combination of compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0074934 A1
- Document ID: US20100074934A1
- Status: Published application
- Kind: A1
- Application number: 12/518,962
- Filed: 2007-12-12
- Published: 2010-03-25
- Earliest claimed: 2006-12-13
- Inventors: William L. Hunter
- Web page: https://patentgrep.com/patent/US20100074934A1

## CPC

- A61F 9/0017: {implantable in, or in contact with, the eye, e.g. ocular inserts}
- A61F 2/16: Intraocular lenses
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61L 27/00: Materials for {grafts or} prostheses or for coating {grafts or} prostheses (dental prostheses A61C13/00; shape or structure of prostheses A61F2/00; use of preparations for artificial teeth A61K6/80; artificial kidneys A61M1/14)
- A61L 27/34: Macromolecular materials
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 29/085: {Macromolecular materials}
- A61L 29/16: Biologically active materials, e.g. therapeutic substances {(A61L29/048 takes precedence)}
- A61L 31/10: Macromolecular materials
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61L 2300/416: Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
- A61L 2300/45: Mixtures of two or more drugs, e.g. synergistic mixtures
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Implants are associated with a combination of paclitaxel or derivatives and dipyridamole or derivatives in order to inhibit fibrosis that may otherwise occur when the implant is placed within an animal. Exemplary implants include intravascular implants (e.g., coronary and peripheral vascular stents, catheters, balloons), non-vascular stents, pumps and sensors, vascular grafts, perivascular devices, implants for hemodialysis access, vena cava filters, implants for providing an anastomotic connection, electrical devices, intraocular implants, and soft tissue implants and fillers.

## Claims

### Claim 1

A device comprising a medical device, paclitaxel and dipyridamole, wherein paclitaxel is present in an amount ranging from about 0.01 to about 1.0 μg/mm2 and dipyridamole is present in an amount ranging from about 0.05 to about 50 μg/mm2 of medical device surface area.

### Claim 2 (depends on 1)

The device of claim 1 wherein paclitaxel is present in an amount ranging from about 0.1 to about 0.6 μg/mm2 and dipyridamole is present in an amount ranging from about 0.5 to about 5 μg/mm2 of medical device surface area.

### Claim 3

A device comprising a medical device, paclitaxel and dipyridamole, wherein paclitaxel is present in an amount ranging from about 0.01 to about 1.0 μg/mm2 and dipyridamole is present in an amount ranging from about 0.01 to about 1.0 μg/mm2 of medical device surface area.

### Claim 4 (depends on 1)

The device of claim 1 further comprising a polymer.

### Claim 5 (depends on 4)

The device of claim 4 wherein the polymer is a non-biodegradable polymer.

### Claim 6 (depends on 4)

The device of claim 4 wherein the polymer is a biodegradable polymer.

### Claim 7 (depends on 1)

The device of claim 1 wherein the medical device is an intravascular device selected from a catheter, a balloon, and a vena cava filter.

### Claim 8 (depends on 1)

The device of claim 1 wherein the medical device is selected from drug delivery pumps, sensors, non-vascular stents, vascular grafts, perivascular devices, implants for hemodialysis access, implants for providing an anastomotic connection, electrical devices, intraocular implants, and soft tissue implants and tissue fillers.

### Claim 9 (depends on 1)

The device of claim 1 wherein the medical device is a coronary stent or a peripheral vascular stent.

### Claim 10 (depends on 1)

The device of claim 1 wherein the paclitaxel has a biological effect, and the effect is greater in the presence of dipyridamole than in the absence of dipyridamole, and the biological effect is to minimize formation of neointimal hyperplasia.

### Claim 11

A composition comprising paclitaxel and dipyridamole, wherein the weight ratio of dipyridamole to paclitaxel exceeds 0.06 to 1.0.

### Claim 12 (depends on 11)

The composition of claim 11 wherein the paclitaxel has a biological effect, and the biological effect is greater in the presence of dipyridamole than in the absence of dipyridamole.

### Claim 13 (depends on 11)

The composition of claim 11 comprising a combination of paclitaxel and dipyridamole, wherein the biological effect of the combination is greater than the sum of the effects of dipyridamole or paclitaxel acting alone.

### Claim 14 (depends on 11)

The composition of claim 11 wherein the composition further comprises a polymer.

### Claim 15 (depends on 14)

The composition of claim 14 wherein the polymer is a non-biodegradable polymer.

### Claim 16 (depends on 14)

The composition of claim 14 wherein the polymer is a biodegradable polymer.

### Claim 17 (depends on 3)

The device of claim 3 further comprising a polymer.

### Claim 18 (depends on 3)

The device of claim 3 wherein the medical device is an intravascular device selected from a catheter, a balloon, and a vena cava filter.

### Claim 19 (depends on 3)

The device of claim 3 wherein the medical device is selected from drug delivery pumps, sensors, non-vascular stents, vascular grafts, perivascular devices, implants for hemodialysis access, implants for providing an anastomotic connection, electrical devices, intraocular implants, and soft tissue implants and tissue fillers.

### Claim 20 (depends on 3)

The device of claim 3 wherein the medical device is a coronary stent or a peripheral vascular stent.

### Claim 21 (depends on 3)

The device of claim 3 wherein the paclitaxel has a biological effect, and the effect is greater in the presence of dipyridamole than in the absence of dipyridamole, and the biological effect is to minimize formation of neointimal hyperplasia.
